Skip to main content
Top

Current Diabetes Reports

Issue 10/2016

Content (14 Articles)

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis

James C. Needell, Danny Zipris

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis

Sherman S. Leung, Josephine M. Forbes, Danielle J. Borg

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Biomarkers of β-Cell Stress and Death in Type 1 Diabetes

Raghavendra G. Mirmira, Emily K. Sims, Farooq Syed, Carmella Evans-Molina

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston and ME McDonnell, Section Editors)

Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model

Matthew F. Bouchonville, Margaret M. Paul, John Billings, Jessica B. Kirk, Sanjeev Arora

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston and ME McDonnell, Section Editors)

Academic Detailing in Diabetes: Using Outreach Education to Improve the Quality of Care

Michael A. Fischer

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Fenofibrate and Diabetic Retinopathy

Jared E. Knickelbein, Akshar B. Abbott, Emily Y. Chew

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Surgery for Diabetic Eye Complications

María H. Berrocal, Luis A. Acaba, Alexandra Acaba

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

Dragana Lovre, Wynn Htun, Carly Carrion, Vivian A. Fonseca

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

SGLT2 Inhibitors: Benefit/Risk Balance

André J. Scheen

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)

Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination

Rudruidee Karnchanasorn, Horng-Yih Ou, James Lin, Lee-Ming Chuang, Ken C. Chiu

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)

Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk

Katie A. Meyer, Brian J. Bennett

Diabetes Epidemiology (N Maruthur, Section Editor)

Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes

Scott J. Pilla, Amy Q. Quan, Emily L. Germain-Lee, David B. Hellmann, Nestoras N. Mathioudakis

Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes

Kimber M. Simmons, Peter A. Gottlieb, Aaron W. Michels

Obesity (J McCaffery, Section Editor)

Salivary Amylase: Digestion and Metabolic Syndrome

Catherine Peyrot des Gachons, Paul A. S. Breslin

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine